Objectives To review the literature and provide an update on the mechanisms of action and
therapeutic uses of oral colchicine in arthritis and inflammatory conditions. Methods We …

Since the second version of the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015, therapeutic …

Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA)
clinical trials that represent both patients' and physicians' priorities. Methods We …

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features,
which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests …

Objective To examine the prevalence of subclinical atherosclerosis in patients with psoriatic
arthritis (PsA) compared with healthy controls, and to identify clinical and biologic markers …

Objective. To include the patient perspective in accordance with the Outcome Measures in
Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set …

Objectives Osteonecrosis of the jaw ( ONJ ) is a potentially severe adverse effect of
bisphosphonates ( BP ). Although the risk of ONJ increases with increasing duration of BP treatment, …

Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease with a chronic,
progressive course. Various aspects of PsA, including its clinical features, disease course and …

Background The objective was to compare different definitions of remission and low disease
activity (LDA) in patients with psoriatic arthritis (PsA), based on both patients’ and physicians…

Objective. The Rasch measurement model provides robust analysis of the internal construct
validity of outcome measures. We reviewed the application of Rasch analysis in …